Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?

QR Code

Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?

Introduction: Cancer is highly adaptable and is constantly evolving against current targeted therapies such as tyrosine kinase inhibitors. Despite advances in recent decades, the emergence of drug resistance to tyrosine kinase inhibitors constantly hampers therapeutic efficacy of cancer treatment. C...

Full description

Bibliographic Details
Main Authors:	Hamdi, Amir Imran Faisal, Soon, Hin How, Islam, Mohammad Kaisarul, Chee, Jonathan Woei Lim, Stanslas, Johnson
Format:	Article
Published:	Taylor and Francis 2022
Online Access:	http://psasir.upm.edu.my/id/eprint/100126/

Similar Items

An apoferritin-based drug delivery system for the tyrosine kinase inhibitor gefitinib
by: Kuruppu, Anchala I., et al.
Published: (2015)

Self-assembling tyrosine kinase inhibitors for localised targeted delivery
by: Al-Ameedee, Mohammed
Published: (2017)

Delaying emergence of resistance to KRAS inhibitors with adaptive therapy: “treatment-to-contain” instead of “treatment-to-cure”
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)

EGFR-directed tyrosine kinase inhibitors for non-small cell lung cancer
by: Fatin Nur Elyana Mohd Sidek,, et al.
Published: (2025)

Benzalhydantoin derivative-based inhibitors of eight receptor tyrosine kinases: synthesis, in-vitro, and in-silico study
by: Muhammad Naufal,, et al.
Published: (2025)

Case series of small cell lung cancer transformation post tyrosine kinase inhibitor failure
by: Chai, C.S., et al.
Published: (2017)

An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
by: Gutteridge, Eleanor
Published: (2010)

Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
by: Carter, Joanne J., et al.
Published: (2016)

Linifanib – a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator
by: Marlow, Maria, et al.
Published: (2015)

Survival rate and prognostic factors of survival among chronic myeloid leukaemia adults after initiation of tyrosine kinase inhibitor therapy in Hospital Ampang, Selangor
by: Ali, Zakiah Bakar
Published: (2024)

Spectroscopic and molecular modeling studies on the interaction of tyrosine kinase inhibitors with human serum albumin / Md. Zahirul Kabir
by: Md. Zahirul , Kabir
Published: (2018)

Resistance mechanisms causing first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment failure
by: Chai, C.S., et al.
Published: (2017)

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure
by: Chee, Shee Chai
Published: (2017)

Case Series of Small Cell Lung Cancer Transformation as Resistance Mechanism to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
by: Liam, C, et al.
Published: (2017)

Circumventing the Feature Association Problem in SLAM
by: Adams, M., et al.
Published: (2013)

Outcome of patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors versus cytotoxic chemotherapy
by: Chai, Chee She
Published: (2015)

Phosphoinositide 3-kinase pathway inhibitors: pharmacology, metabolism & drug development
by: Falasca, Marco
Published: (2011)

Switching principles to circumvent Euler angle singularity
by: Okasha, Mohamed Elsayed Aly Abd Elaziz, et al.
Published: (2010)

Determination of gene expression of tyrosine kinase receptors (HER family) in FFPE tissue of colorectal adenocarcinoma
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)

Effects of receptor tyrosine kinase inhibitors on VEGF165a- and VEGF165b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2
by: Carter, Joanne J., et al.
Published: (2015)

Real-time analysis of the binding of fluorescent VEGF₁₆₅a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes
by: Kilpatrick, Laura E., et al.
Published: (2017)

Role of Focal Adhesion Tyrosine Kinases in GPVI-Dependent Platelet Activation and Reactive Oxygen Species Formation
by: Carrim, N., et al.
Published: (2014)

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
by: Yu, Yu, et al.
Published: (2015)

The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets
by: Canobbio, I., et al.
Published: (2015)

A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study
by: Clark, Richard E., et al.
Published: (2017)

Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview
by: Fischer, Peter M.
Published: (2017)

The proline-rich tyrosine kinase Pyk2 regulates platelet integrin aIIbß3 outside-in signaling
by: Cipolla, L., et al.
Published: (2013)

Trimming, Transforming Statistics, And Bootstrapping: Circumventing the Biasing Effects Of Heterescedasticity And Nonnormality.
by: Keselman, H. J., et al.
Published: (2002)

A randomized control trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia with deep molecular response for at least two years
by: Kuan, Jew-Win, et al.
Published: (2016)

Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca2+-dependent tyrosine kinase Pyk2
by: Canobbio, I., et al.
Published: (2013)

Kinase targets in CNS drug discovery
by: Gunosewoyo, Hendra, et al.
Published: (2017)

Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer
by: Islam, Mohammad Kaisarul, et al.
Published: (2021)

Src family tyrosine kinase Lyn mediates VWF GPIb-IX induced platelet activation via the cGMP signaling pathway
by: Yin, H., et al.
Published: (2008)

Pancreatic cancer treatment with targeted therapies: are we there yet
by: Nwaefulu, O. Ngozi, et al.
Published: (2022)

A qualitative study on the doctrine of privity to circumvent its effect on subcontractor's payment claim
by: See, Zhi Yan, et al.
Published: (2023)

A Qualitative Study On the Doctrine of Privity to Circumvent Its Effect On Subcontractor’s Payment Claim
by: Yan, See Zhi, et al.
Published: (2023)

The tyrosine kinase Pyk2 mediates the cross-talk between platelet integrins alpha 2 beta 1 and alpha IIb beta 3
by: Guidetti, G., et al.
Published: (2011)

The tyrosine kinase PYK2 mediates the cross-talk between platelet integrins alpha 2 beta 1 and alpha iib beta 3
by: Guidetti, G., et al.
Published: (2011)

Molecularly targeted therapies for asthma: current development, challenges and potential clinical translation
by: Sulaiman, Ibrahim, et al.
Published: (2016)

COX-2 inhibitors: a potential target for drug therapy in the management of colorectal cancer
by: Ryan, A R, et al.
Published: (1999)